clofazimine (Lamprene)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Caution:

pregnancy category = -

safety in lactation = -

Dosage

Capsules: 50 & 100 mg.

Pharmacokinetics

  • oral absorption: 45-70%, aborbed slowly
  • tissue distribution
    • distributed principally to fatty tissues & reticulo- endothelial cells
    • appears in breast milk
    • crosses placenta
    • does not distribute into brain or CSF
    • remains in tissues for prolonged periods of time
  • metabolized partially in the liver
  • mainly excreted in the feces
  • elimination 1/2life
    • 70 days (tissue)
    • 8 days (terminal)

elimination via feces

elimination via liver

1/2life = 70 days tissue

1/2life = 8 days terminal

Adverse effects

* pink to brownish-black discoloration of skin, conjunctiva, tears, sweat, urine, feces, nasal secretions; may take months to years to disappear after therapy is complete

Drug interactions

Mechanism of action

More general terms

Additional terms

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  3. 3.0 3.1 Deprecated Reference
  4. Department of Veterans Affairs, VA National Formulary

Database